| | Identification | Back Directory |  | [Name] 
 COG-1410
 |  | [CAS] 
 878009-24-6
 |  | [Synonyms] 
 COG-1410
 L-Leucinamide, N-acetyl-L-alanyl-L-seryl-2-methylalanyl-L-leucyl-L-arginyl-L-lysyl-L-leucyl-2-methylalanyl-L-lysyl-L-arginyl-L-leucyl-
 |  | [Molecular Formula] 
 C64H121N21O14
 |  | [MDL Number] 
 MFCD18072264
 |  | [MOL File] 
 878009-24-6.mol
 |  | [Molecular Weight] 
 1408.78
 | 
 | Chemical Properties | Back Directory |  | [density ] 
 1.32±0.1 g/cm3(Predicted)
 |  | [storage temp. ] 
 Store at -20°C, protect from light, stored under nitrogen
 |  | [solubility ] 
 DMSO : 100 mg/mL (70.98 mM; Need ultrasonic)
 |  | [form ] 
 Solid
 |  | [pka] 
 12.62±0.46(Predicted)
 |  | [color ] 
 White to off-white
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease[1][2].
 |  | [in vivo] 
 
 COG1410 (0.3-0.6 mg/kg; a single i.v.) exhibits significant improvement on a short term test of vestibulomotor function and on a long term test of spatial learning and memory in mice[1].?
COG1410 (0.8 mg/kg; a single i.v.) improves vestibulomotor function, decreases poststroke locomotor asymmetry, and decreases infarct volume of the ipsilateral hemisphere in rats[2].
 | Animal Model: | Male C57Bl/6J mice (12-16 weeks) with TBI[1] |  | Dosage: | 0.3, 0.6 mg/kg |  | Administration: | A single i.v. by tail vein |  | Result: | Improved motor function on days 1-5 postinjury. Significantly improved cognitive impairment.
 Reduced the number of injured hippocampal neurons.
 Suppressed the microglial activation.
 | 
 |  | [storage] 
 Store at -20°C, protect from light, stored under nitrogen
 |  | [References] 
 [1] Laskowitz DT, et, al. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma. 2007 Jul;24(7):1093-107. DOI:10.1089/neu.2006.0192
 [2] Tukhovskaya EA, et, al. COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia. J Neurosci Res. 2009 Feb 15;87(3):677-82. DOI:10.1002/jnr.21874
 [3] Kuai L, et, al. Apolipoprotein E-Mimetic Peptide COG1410 Enhances Retinal Ganglion Cell Survival by Attenuating Inflammation and Apoptosis Following TONI. Front Neurosci. 2019 Sep 13;13:980. DOI:10.3389/fnins.2019.00980
 | 
 |  |